For example, upon gemcitabine resistance acquisition in pancreatic cancer as well as in non-small-cell lung carcinoma, an amplification of one of the main targets of gemcitabine, ribonucleotide reductase catalytic subunit M1 (RRM1), was observed. This evidence concerns the gene RRM1 and familial pancreatic carcinoma.